{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:02:37Z","timestamp":1789225357877,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Liver transplantation (LT) has become widespread in recent years owing to advances in the elucidation of its pathogenesis, surgical procedures, and perioperative management. Historically, LT was only performed in patients with end-stage liver disease and certain malignancies, such as hepatocellular carcinoma, but its indications have recently been expanded to include unresectable perihilar cholangiocarcinoma (pCCA) and colorectal liver metastases (CRLM). In this review, we discuss the current status and future prospects of LT for these expanded indications. Perihilar cholangiocarcinoma and colorectal liver metastasis have poor prognoses if they cannot be surgically resected. For non-resectable pCCA, neoadjuvant chemoradiotherapy followed by LT has demonstrated improved survival, particularly under the Mayo Clinic protocol. Furthermore, LT for CRLM has received renewed interest following encouraging results from a Norwegian group showing a 5-year survival rate of\u2009&gt;\u200980% with strict selection criteria. A recent randomized controlled trial further validated LT with chemotherapy as a promising option, demonstrating a significant survival advantage over chemotherapy alone. Both achieved favorable outcomes by implementing strict patient selection criteria and integrating LT as part of a multidisciplinary treatment approach that includes chemotherapy and radiation therapy. As transplant oncology continues to evolve, a multidisciplinary approach integrating transplant surgery, oncology, and hepatology is crucial for refining LT protocols for non-resectable pCCA and CRLM. Ongoing clinical trials and translational research are key to defining the role of LT in this expanding field, potentially establishing it as a standard therapy for selected cases of advanced hepatic malignancies.<\/jats:p>","DOI":"10.1007\/s10147-025-02820-3","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T10:49:09Z","timestamp":1751712549000},"page":"1472-1481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Liver transplantation as a new treatment option for perihilar cholangiocarcinoma and colorectal liver metastases: a review"],"prefix":"10.1007","volume":"31","author":[{"given":"Ken","family":"Fukumitsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ogiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Anazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamichi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuro","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"issue":"3","key":"2820_CR1","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/SLA.0000000000004071","volume":"273","author":"G Sapisochin","year":"2021","unstructured":"Sapisochin G, Hibi T, Toso C et al (2021) Transplant oncology in primary and metastatic liver tumors: principles, evidence, and opportunities. Ann Surg 273(3):483\u2013493. https:\/\/doi.org\/10.1097\/SLA.0000000000004071","journal-title":"Ann Surg"},{"issue":"7","key":"2820_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/bjs.10556","volume":"105","author":"T Ebata","year":"2018","unstructured":"Ebata T, Mizuno T, Yokoyama Y et al (2018) Surgical resection for Bismuth type IV perihilar cholangiocarcinoma. Br J Surg 105(7):829\u2013838. https:\/\/doi.org\/10.1002\/bjs.10556","journal-title":"Br J Surg"},{"issue":"1","key":"2820_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/BF01658489","volume":"12","author":"R Pichlmayr","year":"1988","unstructured":"Pichlmayr R, Ringe B, Lauchart W et al (1988) Radical resection and liver grafting as the two main components of surgical strategy in the treatment of proximal bile duct cancer. World J Surg 12(1):68\u201377. https:\/\/doi.org\/10.1007\/BF01658489","journal-title":"World J Surg"},{"issue":"5","key":"2820_CR4","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/00000658-199611000-00007","volume":"224","author":"R Pichlmayr","year":"1996","unstructured":"Pichlmayr R, Weimann A, Klempnauer J et al (1996) Surgical treatment in proximal bile duct cancer. A single-center experience. Ann Surg 224(5):628\u2013638. https:\/\/doi.org\/10.1097\/00000658-199611000-00007","journal-title":"Ann Surg"},{"issue":"4","key":"2820_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/s1072-7515(98)00207-5","volume":"187","author":"S Iwatsuki","year":"1998","unstructured":"Iwatsuki S, Todo S, Marsh JW et al (1998) Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 187(4):358\u2013364. https:\/\/doi.org\/10.1016\/s1072-7515(98)00207-5","journal-title":"J Am Coll Surg"},{"issue":"2","key":"2820_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/01.sla.0000108702.45715.81","volume":"239","author":"R Robles","year":"2004","unstructured":"Robles R, Figueras J, Turrion VS et al (2004) Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg 239(2):265\u2013271. https:\/\/doi.org\/10.1097\/01.sla.0000108702.45715.81","journal-title":"Ann Surg"},{"issue":"11","key":"2820_CR7","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/lt.20512","volume":"11","author":"P Ghali","year":"2005","unstructured":"Ghali P, Marotta PJ, Yoshida EM et al (2005) Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl 11(11):1412\u20131416. https:\/\/doi.org\/10.1002\/lt.20512","journal-title":"Liver Transpl"},{"issue":"3","key":"2820_CR8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/01.sla.0000179678.13285.fa","volume":"242","author":"DJ Rea","year":"2005","unstructured":"Rea DJ, Heimbach JK, Rosen CB et al (2005) Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 242(3):451\u2013458. https:\/\/doi.org\/10.1097\/01.sla.0000179678.13285.fa","journal-title":"Ann Surg"},{"issue":"1","key":"2820_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","volume":"143","author":"S Darwish Murad","year":"2012","unstructured":"Darwish Murad S, Kim WR, Harnois DM et al (2012) Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 143(1):88-98 e83. https:\/\/doi.org\/10.1053\/j.gastro.2012.04.008","journal-title":"Gastroenterology"},{"issue":"3","key":"2820_CR10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/lt.26285","volume":"28","author":"T Ito","year":"2022","unstructured":"Ito T, Butler JR, Noguchi D et al (2022) A 3-decade, single-center experience of liver transplantation for cholangiocarcinoma: impact of era, tumor size, location, and neoadjuvant therapy. Liver Transpl 28(3):386\u2013396. https:\/\/doi.org\/10.1002\/lt.26285","journal-title":"Liver Transpl"},{"issue":"2","key":"2820_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/jso.24833","volume":"117","author":"BPT Loveday","year":"2018","unstructured":"Loveday BPT, Knox JJ, Dawson LA et al (2018) Neoadjuvant hyperfractionated chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma in Canada. J Surg Oncol 117(2):213\u2013219. https:\/\/doi.org\/10.1002\/jso.24833","journal-title":"J Surg Oncol"},{"issue":"1","key":"2820_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/hpb.12082","volume":"16","author":"S Duignan","year":"2014","unstructured":"Duignan S, Maguire D, Ravichand CS et al (2014) Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience. HPB Oxford 16(1):91\u201398. https:\/\/doi.org\/10.1111\/hpb.12082","journal-title":"HPB Oxford"},{"issue":"4","key":"2820_CR13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/jhbp.12121","volume":"32","author":"T Ito","year":"2025","unstructured":"Ito T, Taura K, Fukumitsu K et al (2025) Safety and efficacy of living donor liver transplantation for unresectable perihilar cholangiocarcinoma: a single center prospective study. J Hepatobiliary Pancreat Sci 32(4):276\u2013286. https:\/\/doi.org\/10.1002\/jhbp.12121","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"1","key":"2820_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/s1499-3872(14)60013-8","volume":"13","author":"M Rela","year":"2014","unstructured":"Rela M, Rajalingam R, Shanmugam V et al (2014) Novel en-bloc resection of locally advanced hilar cholangiocarcinoma: the rex recess approach. Hepatobiliary Pancreat Dis Int 13(1):93\u201397. https:\/\/doi.org\/10.1016\/s1499-3872(14)60013-8","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"4","key":"2820_CR15","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00268-018-04895-8","volume":"43","author":"E Lahat","year":"2019","unstructured":"Lahat E, Jaber A, Salloum C et al (2019) Porto-rex shunt for left portal vein reconstruction during right extended hepatectomy for advanced extrahepatic biliary cancer. World J Surg 43(4):1117\u20131120. https:\/\/doi.org\/10.1007\/s00268-018-04895-8","journal-title":"World J Surg"},{"issue":"11","key":"2820_CR16","doi-asserted-by":"publisher","first-page":"8249","DOI":"10.1007\/s00464-022-09270-2","volume":"36","author":"M Conticchio","year":"2022","unstructured":"Conticchio M, Salloum C, Allard MA et al (2022) The rex shunt for left portal vein reconstruction during hepatectomy for malignancy using of rex-shunt in adults for oncoliver surgery. Surg Endosc 36(11):8249\u20138254. https:\/\/doi.org\/10.1007\/s00464-022-09270-2","journal-title":"Surg Endosc"},{"issue":"10 Suppl 2","key":"2820_CR17","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1002\/lt.20266","volume":"10","author":"JK Heimbach","year":"2004","unstructured":"Heimbach JK, Haddock MG, Alberts SR et al (2004) Transplantation for hilar cholangiocarcinoma. Liver Transplant 10(10 Suppl 2):S65-68. https:\/\/doi.org\/10.1002\/lt.20266","journal-title":"Liver Transplant"},{"issue":"5","key":"2820_CR18","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/SLA.0000000000002574","volume":"267","author":"CG Ethun","year":"2018","unstructured":"Ethun CG, Lopez-Aguiar AG, Anderson DJ et al (2018) Transplantation Versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease. Ann Surg 267(5):797\u2013805. https:\/\/doi.org\/10.1097\/SLA.0000000000002574","journal-title":"Ann Surg"},{"issue":"5","key":"2820_CR19","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/SLA.0000000000002624","volume":"267","author":"M Nagino","year":"2018","unstructured":"Nagino M (2018) Surgical treatment of perihilar cholangiocarcinoma: resection or transplant? Ann Surg 267(5):806\u2013807. https:\/\/doi.org\/10.1097\/SLA.0000000000002624","journal-title":"Ann Surg"},{"issue":"5","key":"2820_CR20","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/SLA.0000000000002716","volume":"267","author":"CB Rosen","year":"2018","unstructured":"Rosen CB (2018) Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting paradigms for resectable disease in annals of surgery 2018. Ann Surg 267(5):808\u2013809. https:\/\/doi.org\/10.1097\/SLA.0000000000002716","journal-title":"Ann Surg"},{"issue":"8","key":"2820_CR21","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/jhbp.747","volume":"27","author":"M Okuno","year":"2020","unstructured":"Okuno M, Hatano E, Toda R et al (2020) Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-RAS status for unresectable colorectal liver metastasis (BECK study): long-term results of survival. J Hepatobiliary Pancreat Sci 27(8):496\u2013509. https:\/\/doi.org\/10.1002\/jhbp.747","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"2","key":"2820_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/XCS.0000000000000734","volume":"237","author":"L Rajendran","year":"2023","unstructured":"Rajendran L, Claasen MP, McGilvray ID et al (2023) Toronto management of initially unresectable liver metastasis from colorectal cancer in a living donor liver transplant program. J Am Coll Surg 237(2):231\u2013242. https:\/\/doi.org\/10.1097\/XCS.0000000000000734","journal-title":"J Am Coll Surg"},{"issue":"5","key":"2820_CR23","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1097\/SLA.0000000000000786","volume":"261","author":"S Dueland","year":"2015","unstructured":"Dueland S, Guren TK, Hagness M et al (2015) Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer? Ann Surg 261(5):956\u2013960. https:\/\/doi.org\/10.1097\/SLA.0000000000000786","journal-title":"Ann Surg"},{"issue":"5","key":"2820_CR24","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/s1072-7515(02)01498-9","volume":"195","author":"TE Starzl","year":"2002","unstructured":"Starzl TE (2002) The saga of liver replacement, with particular reference to the reciprocal influence of liver and kidney transplantation (1955\u20131967). J Am Coll Surg 195(5):587\u2013610. https:\/\/doi.org\/10.1016\/s1072-7515(02)01498-9","journal-title":"J Am Coll Surg"},{"key":"2820_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22063093","author":"S Puia-Negulescu","year":"2021","unstructured":"Puia-Negulescu S, Lebosse F, Mabrut JY et al (2021) Liver transplantation for colorectal liver metastases: current management and future perspectives. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22063093","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2820_CR26","first-page":"726","volume":"110","author":"I Penn","year":"1991","unstructured":"Penn I (1991) Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 110(4):726\u2013734","journal-title":"Surgery"},{"issue":"1 Pt 2","key":"2820_CR27","first-page":"1567","volume":"23","author":"F Muhlbacher","year":"1991","unstructured":"Muhlbacher F, Huk I, Steininger R et al (1991) Is orthotopic liver transplantation a feasible treatment for secondary cancer of the liver? Transplant Proc 23(1 Pt 2):1567\u20131568","journal-title":"Transplant Proc"},{"issue":"5","key":"2820_CR28","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/SLA.0b013e3182823957","volume":"257","author":"M Hagness","year":"2013","unstructured":"Hagness M, Foss A, Line PD et al (2013) Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg 257(5):800\u2013806. https:\/\/doi.org\/10.1097\/SLA.0b013e3182823957","journal-title":"Ann Surg"},{"issue":"2","key":"2820_CR29","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/SLA.0000000000003404","volume":"271","author":"S Dueland","year":"2020","unstructured":"Dueland S, Syversveen T, Solheim JM et al (2020) Survival following liver transplantation for patients with nonresectable liver-only colorectal metastases. Ann Surg 271(2):212\u2013218. https:\/\/doi.org\/10.1097\/SLA.0000000000003404","journal-title":"Ann Surg"},{"key":"2820_CR30","doi-asserted-by":"publisher","first-page":"175628482092419","DOI":"10.1177\/1756284820924194","volume":"13","author":"A Gangi","year":"2020","unstructured":"Gangi A, Lu SC (2020) Chemotherapy-associated liver injury in colorectal cancer. Therap Adv Gastroenterol 13:1756284820924194. https:\/\/doi.org\/10.1177\/1756284820924194","journal-title":"Therap Adv Gastroenterol"},{"issue":"9","key":"2820_CR31","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1007\/s11864-022-01008-5","volume":"23","author":"MC Riesco-Martinez","year":"2022","unstructured":"Riesco-Martinez MC, Modrego A, Espinosa-Olarte P et al (2022) Perioperative chemotherapy for liver metastasis of colorectal cancer: lessons learned and future perspectives. Curr Treat Options Oncol 23(9):1320\u20131337. https:\/\/doi.org\/10.1007\/s11864-022-01008-5","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"2820_CR32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","volume":"230","author":"Y Fong","year":"1999","unstructured":"Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230(3):309\u2013318. https:\/\/doi.org\/10.1097\/00000658-199909000-00004","journal-title":"Ann Surg"},{"issue":"11","key":"2820_CR33","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S2468-1253(21)00219-3","volume":"6","author":"GK Bonney","year":"2021","unstructured":"Bonney GK, Chew CA, Lodge P et al (2021) Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. Lancet Gastroenterol Hepatol 6(11):933\u2013946. https:\/\/doi.org\/10.1016\/S2468-1253(21)00219-3","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2820_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020345","author":"M Maspero","year":"2023","unstructured":"Maspero M, Sposito C, Virdis M et al (2023) Liver transplantation for hepatic metastases from colorectal cancer: current knowledge and open issues. Cancers. https:\/\/doi.org\/10.3390\/cancers15020345","journal-title":"Cancers"},{"issue":"2","key":"2820_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/SLA.0000000000005703","volume":"278","author":"JM Solheim","year":"2023","unstructured":"Solheim JM, Dueland S, Line PD et al (2023) Transplantation for nonresectable colorectal liver metastases: long-term follow-up of the first prospective pilot study. Ann Surg 278(2):239\u2013245. https:\/\/doi.org\/10.1097\/SLA.0000000000005703","journal-title":"Ann Surg"},{"issue":"3","key":"2820_CR36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/bjs.10651","volume":"105","author":"H Grut","year":"2018","unstructured":"Grut H, Solberg S, Seierstad T et al (2018) Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases. Br J Surg 105(3):295\u2013301. https:\/\/doi.org\/10.1002\/bjs.10651","journal-title":"Br J Surg"},{"issue":"4","key":"2820_CR37","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1245\/s10434-013-3449-9","volume":"21","author":"M Hagness","year":"2014","unstructured":"Hagness M, Foss A, Egge TS et al (2014) Patterns of recurrence after liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg Oncol 21(4):1323\u20131329. https:\/\/doi.org\/10.1245\/s10434-013-3449-9","journal-title":"Ann Surg Oncol"},{"key":"2820_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae367","author":"BE Ueberroth","year":"2025","unstructured":"Ueberroth BE, Kriss M, Burton JR et al (2025) Liver transplantation for colorectal cancer with liver metastases. Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyae367","journal-title":"Oncologist"},{"issue":"1","key":"2820_CR39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/bjs.10962","volume":"106","author":"GMW Bjornelv","year":"2019","unstructured":"Bjornelv GMW, Dueland S, Line PD et al (2019) Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver. Br J Surg 106(1):132\u2013141. https:\/\/doi.org\/10.1002\/bjs.10962","journal-title":"Br J Surg"},{"issue":"10458","key":"2820_CR40","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(24)01595-2","volume":"404","author":"R Adam","year":"2024","unstructured":"Adam R, Piedvache C, Chiche L et al (2024) Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. Lancet 404(10458):1107\u20131118. https:\/\/doi.org\/10.1016\/S0140-6736(24)01595-2","journal-title":"Lancet"},{"key":"2820_CR41","doi-asserted-by":"publisher","first-page":"102608","DOI":"10.1016\/j.eclinm.2024.102608","volume":"72","author":"R Adam","year":"2024","unstructured":"Adam R, Badrudin D, Chiche L et al (2024) Safety and feasibility of chemotherapy followed by liver transplantation for patients with definitely unresectable colorectal liver metastases: insights from the TransMet randomised clinical trial. EClinicalMedicine 72:102608. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102608","journal-title":"EClinicalMedicine"},{"issue":"9","key":"2820_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103669","volume":"9","author":"MM Germani","year":"2024","unstructured":"Germani MM, Raschzok N, Heinemann V et al (2024) Translating efficacy of liver transplantation in liver-limited metastatic colorectal cancer into clinical practice: the TransMet trial. ESMO Open 9(9):103669. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103669","journal-title":"ESMO Open"},{"issue":"6","key":"2820_CR43","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamasurg.2022.0300","volume":"157","author":"R Hernandez-Alejandro","year":"2022","unstructured":"Hernandez-Alejandro R, Ruffolo LI, Sasaki K et al (2022) Recipient and donor outcomes after living-donor liver transplant for unresectable colorectal liver metastases. JAMA Surg 157(6):524\u2013530. https:\/\/doi.org\/10.1001\/jamasurg.2022.0300","journal-title":"JAMA Surg"},{"issue":"11","key":"2820_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-088188","volume":"14","author":"K Fukumitsu","year":"2024","unstructured":"Fukumitsu K, Kageyama S, Ito T et al (2024) Living-donor liver transplantation for non-resectable colorectal liver metastases: protocol for a multicentric, single-arm study. BMJ Open 14(11):e088188. https:\/\/doi.org\/10.1136\/bmjopen-2024-088188","journal-title":"BMJ Open"},{"issue":"6","key":"2820_CR45","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/jamasurg.2021.0267","volume":"156","author":"S Dueland","year":"2021","unstructured":"Dueland S, Yaqub S, Syversveen T et al (2021) Survival outcomes after portal vein embolization and liver resection compared with liver transplant for patients with extensive colorectal cancer liver metastases. JAMA Surg 156(6):550\u2013557. https:\/\/doi.org\/10.1001\/jamasurg.2021.0267","journal-title":"JAMA Surg"},{"issue":"7","key":"2820_CR46","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.hpb.2021.11.015","volume":"24","author":"H Grut","year":"2022","unstructured":"Grut H, Line PD, Labori KJ et al (2022) Survival after liver resection and liver transplantation for colorectal liver metastases: a comparative analysis stratified by metabolic tumor volume assessed by (18)F-FDG PET\/CT. HPB (Oxf) 24(7):1055\u20131062. https:\/\/doi.org\/10.1016\/j.hpb.2021.11.015","journal-title":"HPB (Oxf)"},{"issue":"5","key":"2820_CR47","doi-asserted-by":"publisher","first-page":"109692","DOI":"10.1016\/j.ejso.2025.109692","volume":"51","author":"L Li","year":"2025","unstructured":"Li L, Hirukawa K, Morinaga J et al (2025) Extreme surgery using the hypothermic perfusion technique for conventionally unresectable abdominal malignant tumours: a systematic review and meta-analysis. Eur J Surg Oncol 51(5):109692. https:\/\/doi.org\/10.1016\/j.ejso.2025.109692","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"2820_CR48","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1067\/msy.2000.105500","volume":"127","author":"KJ Oldhafer","year":"2000","unstructured":"Oldhafer KJ, Lang H, Schlitt HJ et al (2000) Long-term experience after ex situ liver surgery. Surgery 127(5):520\u2013527. https:\/\/doi.org\/10.1067\/msy.2000.105500","journal-title":"Surgery"},{"issue":"15","key":"2820_CR49","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1056\/NEJMoa2031532","volume":"384","author":"R van Rijn","year":"2021","unstructured":"van Rijn R, Schurink IJ, de Vries Y et al (2021) Hypothermic machine perfusion in liver transplantation - a randomized trial. N Engl J Med 384(15):1391\u20131401. https:\/\/doi.org\/10.1056\/NEJMoa2031532","journal-title":"N Engl J Med"},{"issue":"4","key":"2820_CR50","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1002\/hep.31234","volume":"72","author":"B Schwacha-Eipper","year":"2020","unstructured":"Schwacha-Eipper B, Minciuna I, Banz V et al (2020) Immunotherapy as a downstaging therapy for liver transplantation. Hepatology 72(4):1488\u20131490. https:\/\/doi.org\/10.1002\/hep.31234","journal-title":"Hepatology"},{"key":"2820_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246307","author":"Q Gao","year":"2021","unstructured":"Gao Q, Anwar IJ, Abraham N et al (2021) Liver transplantation for hepatocellular carcinoma after downstaging or bridging therapy with immune checkpoint inhibitors. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13246307","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2820_CR52","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/ajt.15617","volume":"20","author":"MF Nordness","year":"2020","unstructured":"Nordness MF, Hamel S, Godfrey CM et al (2020) Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient? Am J Transplant 20(3):879\u2013883. https:\/\/doi.org\/10.1111\/ajt.15617","journal-title":"Am J Transplant"},{"key":"2820_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2021.101386","volume":"66","author":"GH Chen","year":"2021","unstructured":"Chen GH, Wang GB, Huang F et al (2021) Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period. Transpl Immunol 66:101386. https:\/\/doi.org\/10.1016\/j.trim.2021.101386","journal-title":"Transpl Immunol"},{"issue":"5","key":"2820_CR54","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","volume":"25","author":"HA Burris 3rd","year":"2024","unstructured":"Burris HA 3rd, Okusaka T, Vogel A et al (2024) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 25(5):626\u2013635. https:\/\/doi.org\/10.1016\/S1470-2045(24)00082-2","journal-title":"Lancet Oncol"},{"issue":"8","key":"2820_CR55","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, He AR, Bouattour M et al (2024) Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol 9(8):694\u2013704. https:\/\/doi.org\/10.1016\/S2468-1253(24)00095-5","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10391","key":"2820_CR56","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401(10391):1853\u20131865. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4","journal-title":"Lancet"},{"issue":"6","key":"2820_CR57","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/lt.26387","volume":"28","author":"X Yan","year":"2022","unstructured":"Yan X, Huang S, Yang Y et al (2022) Sirolimus or everolimus improves survival after liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis. Liver Transpl 28(6):1063\u20131077. https:\/\/doi.org\/10.1002\/lt.26387","journal-title":"Liver Transpl"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02820-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02820-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02820-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:35:41Z","timestamp":1784997341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02820-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2820"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02820-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,5]]},"assertion":[{"value":"3 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}